UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rules 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

 

For the month of November 2021

Commission File Number: 001-38836

 

BIOCERES CROP SOLUTIONS CORP.

(Translation of registrant’s name into English)

 

Ocampo 210 bis, Predio CCT, Rosario

Province of Santa Fe, Argentina

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F  x                                                                                 Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 

EXPLANATORY NOTE

 

This Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (Registration No. 333-249770) and Form S-8 (Registration No. 333-255635), and the following exhibit is filed as part of this Form 6-K:

 

Exhibit List

 

Exhibit No.    Description 
99.1   Bioceres Crop Solutions Corp. unaudited interim condensed consolidated financial statements as of September 30, 2021 and June 30, 2021, and for the three-month periods ended September 30, 2021 and 2020.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    BIOCERES CROP SOLUTIONS CORP.
    (Registrant)
       
       
Dated: November 30, 2021 By: By: /s/ Federico Trucco
    Name: Federico Trucco
    Title: Chief Executive Officer

 

 

 

 

BIOCERES CROP SOLUTIONS CORP.
Unaudited interim condensed consolidated financial
statements as of September 30, 2021 and June 30, 2021,
and for the three-month periods ended September 30,
2021, and 2020.    

 

     

 

 

 

 

INDEX

 

Unaudited interim condensed consolidated financial statements as of September 30, 2021, June 30, 2021 and for the three-month periods ended September 30, 2021 and 2020.  
 
Unaudited interim condensed consolidated statements of financial position as of September 30, 2021 and June 30, 2021 F-3
   
Unaudited interim condensed consolidated statements of comprehensive income for the three-month periods ended September 30, 2021 and 2020 F-5
   
Unaudited interim condensed consolidated statements of changes in equity for the three-month periods ended September 30, 2021 and 2020 F-7
   
Unaudited interim condensed consolidated statements of cash flows for the three-month periods ended September 30, 2021 and 2020 F-9
   
Notes to the unaudited interim condensed consolidated financial statements F-11

 

  F-2  

 

 

 

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

 

As of September 30, 2021, and June 30, 2021

(Amounts in US Dollars)

 

    Notes   09/30/2021     06/30/2021  
ASSETS                    
CURRENT ASSETS                    
Cash and cash equivalents   6.1     36,631,549       36,046,113  
Other financial assets   6.2     5,283,685       11,161,398  
Trade receivables   6.3     94,809,859       88,784,172  
Other receivables   6.4     15,528,441       11,153,705  
Income and minimum presumed income taxes recoverable   8     969,921       990,881  
Inventories   6.5     72,551,919       61,037,551  
Biological assets   6.6     37,879,003       2,315,838  
Total current assets         263,654,377       211,489,658  
                     
NON-CURRENT ASSETS                    
Other financial assets   6.2     935,851       1,097,462  
Trade receivables   6.3     128,575       135,739  
Other receivables   6.4     1,644,765       2,543,142  
Income and minimum presumed income taxes recoverable   8     14,867       12,589  
Deferred tax assets   8     3,802,891       3,278,370  
Investments in joint ventures and associates   12     31,876,966       30,657,173  
Property, plant and equipment   6.7     48,078,743       47,954,596  
Intangible assets   6.8     70,287,443       67,342,362  
Goodwill   6.9     30,468,839       28,751,206  
Right of use asset   18     1,407,154       1,327,660  
Total non-current assets         188,646,094       183,100,299  
Total assets         452,300,471       394,589,957  

 

The accompanying Notes are an integral part of these unaudited interim condensed consolidated financial statements. Related parties’ balances and transactions are disclosed in Note 15.

 

  F-3  

 

 

 

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

 

As of September 30, 2021, and June 30, 2021

(Amounts in US Dollars)

 

LIABILITIES   Notes   09/30/2021     06/30/2021  
CURRENT LIABILITIES                    
Trade and other payables   6.10     113,963,318       72,091,408  
Borrowings   6.11     66,655,578       76,785,857  
Employee benefits and social security   6.12     5,214,001       4,680,078  
Deferred revenue and advances from customers         5,302,738       6,277,313  
Income tax payable   8     10,520,678       7,452,891  
Government grants         306       -  
Lease liabilities   18     718,966       750,308  
Total current liabilities         202,375,585       168,037,855  
                     
NON-CURRENT LIABILITIES                    
Borrowings   6.11     62,644,168       47,988,468  
Government grants         -       784  
Joint ventures and associates   12     1,276,639       1,278,250  
Deferred tax liabilities   8     24,965,998       25,699,495  
Provisions         438,816       449,847  
Consideration for acquisition   6.13     12,075,576       11,790,533  
Convertible notes         50,190,617       48,664,012  
Lease liabilities   18     490,101       390,409  
Total non-current liabilities         152,081,915       136,261,798  
Total liabilities         354,457,500       304,299,653  
                     
EQUITY                    
Equity attributable to owners of the parent         73,748,044       67,743,242  
Non-controlling interests         24,094,927       22,547,062  
Total equity         97,842,971       90,290,304  
Total equity and liabilities         452,300,471       394,589,957  

 

The accompanying Notes are an integral part of these unaudited interim condensed consolidated financial statements. Related parties’ balances and transactions are disclosed in Note 15.

 

  F-4  

 

 

 

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

 

For the three-month periods ended September 30, 2021 and 2020

(Amounts in US Dollars)

 

        Three-month period ended  
    Notes   09/30/2021     09/30/2020  
Revenues from contracts with customers   7.1     66,353,874       42,105,290  
Government grants         468       604  
Initial recognition and changes in the fair value of biological assets         551,903       249,367  
Total         66,906,245       42,355,261  
                     
Cost of sales   7.2     (37,882,453 )     (23,112,642 )
Research and development expenses   7.3     (1,431,542 )     (1,024,212 )
Selling, general and administrative expenses   7.4     (16,183,200 )     (10,092,243 )
Share of profit or loss of joint ventures and associates   12     (222,236 )     239,712  
Other income or expenses, net         (1,146,617 )     5,190  
Operating profit         10,040,197       8,371,066  
                     
Financial cost   7.5     (3,342,809 )     (5,276,050 )
Other financial results   7.5     (1,836,859 )     (7,459,412 )
Profit (loss) before income tax         4,860,529       (4,364,396 )
Income tax   8     (2,595,313 )     (2,005,866 )
Profit (loss) for the period         2,265,216       (6,370,262 )
                     
Profit (loss) for the period attributable to:                    
Equity holders of the parent         874,137       (6,971,558 )
Non-controlling interests         1,391,079       601,296  
          2,265,216       (6,370,262 )
                     
Profit (loss) per share                    
Basic profit (loss) attributable to ordinary equity holders of the parent 1   9     0.0213       (0.1917 )
Diluted profit (loss) attributable to ordinary equity holders of the parent   9     0.0206       (0.1917 )
Weighted average number of shares                    
Basic 1   9     41,104,088       36,367,953  
Diluted   9     42,376,794       36,367,953  

 

(1)  For the three-month period ended September 30, 2020 diluted EPS was the same as basic EPS. See note 9.

 

The accompanying Notes are an integral part of these unaudited interim condensed consolidated financial statements. Related parties’ balances and transactions are disclosed in Note 15.

 

  F-5  

 

 

 

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

 

For the three-month periods ended September 30, 2021 and 2020

(Amounts in US Dollars)

 

    Three-month period ended  
    09/30/2021     09/30/2020  
Profit (loss) for the period     2,265,216       (6,370,262 )
                 
Other comprehensive income     5,729,137       136,131  
Items that may be subsequently reclassified to profit and loss     7,118,021       13,796  
Exchange differences on translation of foreign operations from joint ventures     1,617,492       (76,438 )
Exchange differences on translation of foreign operations     5,500,529       90,234  
Items that will not be subsequently reclassified to loss and profit     (1,388,884 )     122,335  
Revaluation of property, plant and equipment, net of tax, of joint ventures and associates 2     (173,852 )     14,135  
Revaluation of property, plant and equipment, net of tax 3     (1,215,032 )     108,200  
Total comprehensive profit (loss)     7,994,353       (6,234,131 )
                 
Total comprehensive profit (loss) attributable to:                
Equity holders of the parent     5,722,059       (7,033,867 )
Non-controlling interests     2,272,294       799,736  
      7,994,353       (6,234,131 )

 

(2) The tax effect of the revaluation of property, plant and equipment of joint ventures and associates was $ 93,613 and $ (4,712) for the three-month periods ended September 30, 2021 and 2020, respectively.

 

(3) The tax effect of the revaluation of property, plant and equipment was $ 654,248 and $(36,067) for the three-month periods ended September 30, 2021 and 2020, respectively.

 

The accompanying Notes are an integral part of these unaudited interim condensed consolidated financial statements. Related parties’ balances and transactions are disclosed in Note 15.

 

  F-6  

 

 

 

 

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

For the three-month periods ended September 30, 2021 and 2020

 

(Amounts in US Dollars)

 

    Attributable to the equity holders of the parent              
Description   Issued
capital
    Share
premium
    Own shares
trading
premium
    Stock
options and
share based
incentives
    Convertible
instruments
    Cost of own
shares held
    Retained
deficit
    Foreign
currency
translation
reserve
    Revaluation
of PP&E
and effect of
tax rate
change
    Equity
attributable
to owners of
the parent
    Non-
controlling
Interests
    Total equity  
06/30/2020     3,613       96,486,865       -       3,428,029       702,981       (30,906 )     (18,613,112 )     (43,198,201 )     7,400,126       46,179,395       14,570,087       60,749,482  
Capitalization of warrants     260       7,765,410       (916,202 )     -       -       -       -       -       -       6,849,468       -       6,849,468  
Share-based incentives     -       -       -       316,703       -       -       -       -       -       316,703       -       316,703  
Purchase of own shares     -       -       -       -       -       (529,278 )     -       -       -       (529,278 )     -       (529,278 )
(Loss) profit for the period     -       -       -       -       -       -       (6,971,558 )     -       -       (6,971,558 )     601,296       (6,370,262 )
Other comprehensive income or loss     -       -       -       -       -       -       -       (160,177 )     97,868       (62,309 )     198,440       136,131  
09/30/2020     3,873       104,252,275       (916,202 )     3,744,732       702,981       (560,184 )     (25,584,670 )     (43,358,378 )     7,497,994       45,782,421       15,369,823       61,152,244  

 

As of September 30, 2020, we have 226,325 of our own shares.

 

The accompanying Notes are an integral part of these unaudited interim condensed consolidated financial statements. Related parties’ balances and transactions are disclosed in Note 15.

 

  F-7  

 

 

 

 

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

For the three-month periods ended September 30, 2021 and 2020

 

(Amounts in US Dollars)

 

    Attributable to the equity holders of the parent              
Description   Issued
capital
    Share
premium
    Changes in
non-
controlling
interests
    Own shares
trading
premium
    Stock
options and
share based
incentives
    Convertible
instruments
    Cost of own
shares held
    Retained
deficit
    Foreign
currency
translation
reserve
    Revaluation
of PP&E and
effect of tax
rate change
    Equity /
(deficit)
attributable
to owners
of the
parent
    Non-
controlling
Interests
    Total
equity
 
06/30/2021     4,158       120,662,386       -       (916,202 )     3,672,768       702,981       (3,530,926 )     (25,483,275 )     (32,622,808 )     5,254,160       67,743,242       22,547,062       90,290,304  
Share-based incentives (Note 17)     -       -       -       -       538,636       -       -       -       -       -       538,636       -       538,636  
Changes in non-controlling interests     -       -       (255,893 )     -       -       -       -       -       -       -       (255,893 )     (724,429 )     (980,322 )
Profit for the period     -       -       -       -       -       -       -       874,137       -       -       874,137       1,391,079       2,265,216  
Other comprehensive income or (loss)     -       -       -       -       -       -       -       -       5,959,029       (1,111,107 )     4,847,922       881,215       5,729,137  
09/30/2021     4,158       120,662,386       (255,893 )     (916,202 )     4,211,404       702,981       (3,530,926 )     (24,609,138 )     (26,663,779 )     4,143,053       73,748,044       24,094,927       97,842,971  

 

As of September 30, 2021, we have 464,455 of our own shares.

 

The accompanying Notes are an integral part of these unaudited interim condensed consolidated financial statements. Related parties’ balances and transactions are disclosed in Note 15.

 

  F-8  

 

 

 

 

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the three-month periods ended September 30, 2021 and 2020

 

(Amounts in US Dollars)

 

    Notes     09/30/2021     09/30/2020  
OPERATING ACTIVITIES                        
Profit (loss) for the period             2,265,216       (6,370,262 )
                         
Adjustments to reconcile profit to net cash flows                        
Income tax             2,595,313       2,005,866  
Finance results             5,179,668       12,735,462  
Depreciation of property, plant and equipment     6.7       946,344       534,655  
Amortization of intangible assets     6.8       672,887       529,477  
Depreciation of leased assets     18       240,154       93,167  
Transactional expenses             -       700,000  
Share-based incentive and stock options             538,636       316,703  
Share of profit or loss of joint ventures and associates     12       222,236       (239,712 )
Provisions for contingencies             2,742       36,321  
Allowance for impairment of trade debtors             197,642       96,931  
Allowance for obsolescence             440,324       192,170  
Initial recognition and changes in the fair value of biological assets             (551,903 )     (249,367 )
Gain or loss on sale of equipment and intangible assets             (42,639 )     (39,871 )
                         
Working capital adjustments                        
Trade receivables             (6,130,427 )     (900,927 )
Other receivables             (3,750,061 )     (5,779,106 )
Income and minimum presumed income taxes             2,989,781       596,708  
Inventories and biological assets             (51,035,721 )     (5,124,373 )
Trade and other payables             38,528,315       (5,511,875 )
Employee benefits and social security             491,886       (254,546 )
Deferred revenue and advances from customers             (1,051,306 )     (1,236,992 )
Income and minimum presumed income taxes paid             (146,317 )     -  
Government grants             (478 )     (858 )
Interest collected             975,051       974,461  
Inflation effects on working capital adjustments             (7,321,037 )     (606,310 )
Net cash flows used in operating activities             (13,743,694 )     (7,502,278 )

 

The accompanying Notes are an integral part of these unaudited interim condensed consolidated financial statements. Related parties’ balances and transactions are disclosed in Note 15.

 

  F-9  

 

 

 

 

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the three-month periods ended September 30, 2021 and 2020

 

(Amounts in US Dollars)

 

    Notes     09/30/2021     09/30/2020  
INVESTMENT ACTIVITIES                        
Proceeds from sale of property, plant and equipment             198,043       41,930  
Proceeds from financial assets             4,997,025       -  
Investment in financial assets             (450,253 )     (525,903 )
Purchase of property, plant and equipment     6.7       (779,401 )     (1,067,553 )
Acquisition of investment property             -       (561,746 )
Capitalized development expenditures     6.8       (1,587,042 )     (439,934 )
Purchase of intangible assets     6.8       (192,133 )     (282,452 )
Net cash flows generated (used in) by investing activities             2,186,239       (2,835,658 )
                         
FINANCING ACTIVITIES                        
Proceeds from borrowings             39,875,454       42,430,825  
Repayment of borrowings, financed payments and interest payments             (24,450,337 )     (29,818,977 )
(Decrease) increase in bank overdrafts and other short-term borrowings             (32,838 )     1,909,507  
Other financial proceeds or payments, net             (1,569,712 )     97,897  
Acquisition of non-controlling interest in subsidiaries             (724,429 )     -  
Purchase of own shares             -       (529,278 )
Leased assets payments             (243,783 )     (158,985 )
Warrants tender offer payments             -       (1,030,952 )
Net cash flows generated by financing activities             12,854,355       12,900,037  
                         
Net increase in cash and cash equivalents             1,296,900       2,562,101  
                         
Inflation effects on cash and cash equivalents             (1,477,981 )     (240,142 )
                         
Cash and cash equivalents as of beginning of the period     6.1       36,046,113       27,159,421  
Effect of exchange rate changes on cash and equivalents             766,517       507,256  
Cash and cash equivalents as of the end of the period     6.1       36,631,549       29,988,636  

 

The accompanying Notes are an integral part of these unaudited interim condensed consolidated financial statements. Related parties’ balances and transactions are disclosed in Note 15.

 

  F-10  

 

 

 

 

Index

 

1. General information.

 

2. Accounting standards and basis of preparation.

 

3. New standards, amendments and interpretations issued by the IASB.

 

4. Impact of COVID-19.

 

5. Seasonality.

 

6. Information about components of unaudited interim condensed consolidated statements of financial position.

 

7. Information about components of unaudited interim condensed consolidated statement of comprehensive income.

 

8. Taxation.

 

9. Earnings per share.

 

10. Information about unaudited condensed consolidated components of equity.

 

11. Cash flow information.

 

12. Joint ventures and associates.

 

13. Segment information.

 

14. Financial instruments – Risk management.

 

15. Shareholders and other related parties’ balances and transactions.

 

16. Key management personnel compensation.

 

17. Share-based payments.

 

18. Leases.

 

19. Contingencies, commitments, and restrictions on the distribution of profits.

 

20. Events occurring after the reporting period.

 

  F-11  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

1. GENERAL INFORMATION

 

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is a fully integrated provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The Group has a unique biotech platform with high impact, patented technologies for seeds and microbial ag-inputs, as well as next generation crop nutrition and protection solutions.

 

Bioceres is a global company with an extensive geographic footprint. The Group’s agricultural inputs are marketed across more than 30 countries, mainly in Argentina, Brazil, United States, Europe and South Africa.

 

Unless the context otherwise requires, “we”, “us”, “our”, “Bioceres”, “BIOX”, “the Group”, and “Bioceres Crop Solutions” will refer to Bioceres Crop Solutions Corp. and its subsidiaries.

 

2. ACCOUNTING STANDARDS AND BASIS OF PREPARATION

 

Statement of compliance with IFRS as issued by IASB

 

These unaudited interim condensed consolidated financial statements for the three-month period ended September 30, 2021, have been prepared in accordance with Accounting Standard IAS 34 Interim Financial Reporting.

 

These unaudited interim condensed consolidated financial statements do not include all notes of the type normally included in an annual financial statement. Accordingly, these unaudited interim condensed consolidated financial statements are to be read in conjunction with the consolidated financial statements as of June 30, 2021.

 

Authorization for the issue of the unaudited interim condensed consolidated financial statements

 

These unaudited interim condensed consolidated financial statements of the Group as of September 30, 2021, June 30, 2021 and for the three-month periods ended September 30, 2021 and 2020 were authorized by the Board of Directors of Bioceres Crop Solutions Corp. on November 29, 2021.

 

Basis of measurement

 

The unaudited interim condensed consolidated financial statements of the Group have been prepared using:

 

·     Going Concern Basis of Accounting, considering the conclusion of the assessment made by the Management about the ability of the Group and its subsidiaries to continue as a going concern, in accordance with the requirements of paragraph 25 of IAS 1, “Presentation of Financial Statements”.

 

·     Accrual Basis of Accounting (except for cash flows information). Under this basis of accounting, the effects of transactions and other events are recognized as they occur, even when there are no cash flows.

 

Functional currency and presentation currency

 

a)            Functional currency

 

Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic market in which the entity operates (i.e., “the functional currency”).

 

IAS 29 “Financial reporting in hyperinflationary economies” requires that the financial statements of an entity whose functional currency is the currency of a hyperinflationary economy, whether these are based on the historical cost method or the current cost method, be stated in terms of the measuring unit current at the closing date of the reporting period. For such purpose, the inflation produced since the acquisition date or the revaluation date, as applicable, must be computed in non-monetary items. The standard details a series of factors to be considered for concluding whether an economy is hyperinflationary, including, but not limited to, a cumulative inflation rate over a three-year period that approaches or exceeds 100%. Inflation accumulated in three years, as of June 30, 2018, was over 100%. It was for this reason that, in accordance with IAS 29, the Argentine economy had to be considered as hyperinflationary since July 1, 2018. Consequently, the Group has applied IAS 29 to these financial statements.

 

  F-12  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

In an inflationary period, any entity that maintains an excess of monetary assets over monetary liabilities, will lose purchasing power, and any entity that maintains an excess of monetary liabilities over monetary assets, will gain purchasing power, provided that such items are not subject to an adjustment mechanism.

 

Briefly, the restatement mechanism of IAS 29 establishes that monetary assets and liabilities will not be restated because they are already expressed in a current unit of measurement at the end of the reporting period. Assets and liabilities subject to adjustments based on specific agreements, will be adjusted according to those agreements. Non-monetary items measured at their current values at the end of the reporting period, such as the net realizable value or others, do not need to be restated. The remaining non-monetary assets and liabilities will be restated according to a general price index. The loss or gain for the net monetary position will be included in the net result of the reporting period, revealing this information in a separate line item.

 

The inflation adjustment to the initial balances was calculated by means of a conversion factor derived from the Argentine price indexes published by the National Institute of Statistics.

 

The index as of September 30, 2020 and June 30, 2020 was 346.6207 and 321.9738, respectively.

 

The index as of September 30, 2021 and June 30, 2021 was 528.4968 and 483.6049, respectively.

 

The comparative figures in these unaudited interim condensed consolidated financial statements presented in a stable currency are not adjusted for subsequent changes in the price levels or exchange rates.

 

b)            Presentation currency

 

The unaudited interim condensed consolidated financial statements of the Group are presented in US Dollars, which is the presentation currency.

 

c)            Foreign currency

 

Transactions entered into by Group entities in a currency other than their functional currency are recorded at the relevant exchange rates as of the date upon which such transactions occur. Foreign currency monetary assets and liabilities are translated at the prevailing exchanges rates as of the final day of each reporting period. Exchange differences arising from the retranslation of unsettled monetary assets and liabilities are recognized immediately in profit or loss, except for foreign currency borrowings qualifying as a hedge of a net investment in a foreign operation for which exchange differences are recognized in other comprehensive income and accumulated in the foreign exchange reserve along with the exchange differences arising from the retranslation of the foreign operation. Upon the disposal of a foreign operation, the cumulative exchange differences recognized in the foreign exchange reserve relating to such operation up to the date of disposal are transferred to the consolidated statement of profit or loss and other comprehensive income as part of the gain or loss recognized upon such disposal.

 

Changes in accounting policies

 

The accounting policies adopted in the preparation of these unaudited interim condensed consolidated financial statements are consistent with those adopted for the preparation of the consolidated financial statements as of June 30, 2021.

 

  F-13  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

3. NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS ISSUED BY THE IASB

 

a) The following new standards became applicable for the current reporting period and adopted by the Group. These amendments did not have a material impact on the Group.

 

Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 - Interest Rate Benchmark Reform (Phase 2)

 

The Phase 2 amendments, Interest Rate Benchmark Reform—Phase 2, address issues that might affect financial reporting during the reform of an interest rate benchmark, including the effects of changes to contractual cash flows or hedging relationships arising from the replacement of an interest rate benchmark with an alternative benchmark rate (replacement issues). In 2019, the Board issued its initial amendments in Phase 1 of the project.

 

The amendments are related to changes in the basis for determining contractual cash flows of financial assets, financial liabilities and lease liabilities; hedge accounting; and disclosures. They apply only to changes required by the interest rate benchmark reform to financial instruments and hedging relationships.

 

The amendments are effective for financial years beginning on or after January 1, 2021. Earlier application is permitted.

 

Covid-19-Related Rent Concessions beyond 30 June 2021

 

The International Accounting Standards Board extended by one year the application period of the practical expedient in IFRS 16 Leases to help lessees accounting for covid-19-related rent concessions.

 

In response to calls from stakeholders and because the covid-19 pandemic is still at its height, the Board has extended the relief by one year to cover rent concessions that reduce only lease payments due on or before 30 June 2022.

 

The original amendment permitted lessees, as a practical expedient, not to assess whether particular rent concessions occurring as a direct consequence of the covid-19 pandemic are lease modifications and, instead, to account for those rent concessions as if they were not lease modifications.

 

The amendment is effective for annual reporting periods beginning on or after 1 April 2021.

 

New standards and interpretations not yet adopted by the Group

 

No new standards have been issued in the current reporting period.

 

4. IMPACT OF COVID-19

 

In December 2019, a novel strain of coronavirus (“COVID-19”) was reported in Wuhan, China. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic. COVID-19 has disrupted business activities in Argentina and worldwide. The Group’s operations, which involve agricultural production and commercialization activities, have been mostly exempted from the disruption. Consequently, our financial condition, liquidity position and results of operations have not been materially impacted as we have been allowed to continue with our operations.

 

The eventual scope of the Coronavirus outbreak and its impact on the countries and global economy are unknown, with governments being able to implement stricter containment measures, which are not predictable in this instance. It cannot be reasonably quantified to what extent the Coronavirus will affect the Company's business and the results of its operations in the future if this situation is prolonged. The Board of Directors and senior management are closely monitoring the situation and taking all necessary measures at their disposal to protect human life and the Group’s operations and financial condition.

 

  F-14  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

5. SEASONALITY

 

The Group revenues fluctuate depending on the timing of orders from our distributors and customers and on prevailing seed market prices, which influence the purchase decisions of growers, the end-users of seed and integrated products, crop protection products and crop nutrition products. Given the cyclicality of crop planting and harvesting and South America’s planting and growing seasons, which vary from year to year, our business is highly seasonal. This results in substantial fluctuations in quarterly sales and profitability. Generally, the Group sales are concentrated in the third and fourth quarters of each calendar year, when demand for seed and integrated products, crop protection products and crop nutrition products increases as South American growers begin planting their fields. Regarding the seed and integrated products business, the Group contracts with growers and seed suppliers based upon anticipated market demand that we forecast. Generally, in the seed and integrated products business we stock the seed during the harvest season and ship from inventory throughout the year, with the objective of selling most of the inventory from the current year’s harvest before the next year’s, with crop protection and crop nutrition business following a cycle similar to the seed cycle. The impact of seasonality and the resulting fluctuations in quarterly results may be lessened as we achieve our international expansion plans for the seed and integrated products business in geographies with complementary seasons and climates.

 

6.     INFORMATION ABOUT COMPONENTS OF UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

 

6.1. Cash and cash equivalents

 

    09/30/2021     06/30/2021  
Cash at bank and on hand     30,082,841       28,327,569  
Money market funds     6,548,708       7,718,544  
      36,631,549       36,046,113  

 

6.2. Other financial asset

 

    09/30/2021     06/30/2021  
Current                
Restricted short-term deposits     252,474       425,976  
US Treasury bills     2,513,798       7,885,937  
Other investments     2,517,413       2,849,485  
      5,283,685       11,161,398  

 

    09/30/2021     06/30/2021  
Non-current                
Shares of Bioceres S.A.     376,288       355,251  
Other investments     559,563       742,211  
      935,851       1,097,462  

 

  F-15  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

6.3. Trade receivables

 

    09/30/2021     06/30/2021  
Current                
Trade debtors     84,883,913       87,709,287  
Allowance for impairment of trade debtors     (5,819,700 )     (5,858,503 )
Shareholders and other related parties (Note 15)     (78,474 )     -  
Allowance for impairment of shareholders and other related parties (Note 15)     43,345       -  
Allowance for credit notes to be issued     (1,572,371 )     (2,987,398 )
Trade debtors - Joint ventures and associates (Note 15)     57,706       221,048  
Deferred checks     17,295,440       9,699,738  
      94,809,859       88,784,172  
Non-current                
Trade debtors     128,575       135,739  
      128,575       135,739  

 

6.4. Other receivables

 

    09/30/2021     06/30/2021  
Current                
Taxes     8,065,060       6,048,533  
Other receivables - Other related parties (Note 15)     1,499       1,547  
Other receivables - Parents companies and related parties to Parents (Note 15)     1,052,879       770,549  
Other receivables - Joint ventures and associates (Note 15)     2,375,118       2,219,863  
Prepayments to suppliers     3,396,211       1,646,614  
Prepayments to suppliers - Shareholders and other related parties (Note 15)     128,565       132,625  
Reimbursements over exports     10,548       10,547  
Prepaid expenses and other receivables     184,938       1,021  
Loans receivable     -       230,000  
Miscellaneous     313,623       92,406  
      15,528,441       11,153,705  

 

    09/30/2021     06/30/2021  
Non-current                
Taxes     170,150       862,771  
Reimbursements over exports     1,474,615       1,680,371  
      1,644,765       2,543,142  

 

  F-16  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS 

(Amounts in US Dollars, except otherwise indicated)

 

6.5. Inventories

 

    09/30/2021     06/30/2021  
Agrochemicals     1,012,575       1,161,025  
Seeds and grains     1,323,942       404,774  
Resale products     27,848,800       20,207,496  
Manufactured products     16,213,582       10,902,683  
Goods in transit     2,076,596       1,169,303  
Supplies     9,270,594       6,320,594  
Agricultural products     16,054,607       21,984,626  
Allowance for obsolescence     (1,248,777 )     (1,112,950 )
      72,551,919       61,037,551  
                 
Net of Agricultural products     56,497,312       39,052,925  

 

6.6. Biological assets

 

Changes in biological assets

 

    Soybean     Corn     Wheat     Barley     HB4
Wheat
    Total  
Beginning of the period     54,162       27,646       22,311       3,071       2,208,648       2,315,838  
Initial recognition and changes in the fair value of biological assets     -       -       9,275       -       542,628       551,903  
Costs incurred during the period     118,984       148,549       67,594       21,877       34,999,130       35,356,134  
Exchange differences     (3,479 )     (3,120 )     (10,992 )     (429 )     (326,852 )     (344,872 )
Period ended September 30, 2021     169,667       173,075       88,188       24,519       37,423,554       37,879,003  

 

    Soybean     Corn     Wheat     Barley     HB4
Wheat
    Total  
Beginning of the period     105,101       271,754       45,639       34,050       509,184       965,728  
Initial recognition and changes in the fair value of biological assets     -       73,267       151,863       24,237       -       249,367  
Decrease due to harvest / disposals     (97,199 )     (118,943 )     -       (31,490 )     -       (247,632 )
Costs incurred during the period     -       -       231,023       40,811       1,725,754       1,997,588  
Exchange differences     (7,902 )     (20,431 )     (18,237 )     (4,094 )     -       (50,664 )
Period ended September 30, 2020     -       205,647       410,288       63,514       2,234,938       2,914,387  

 

6.7. Property, plant and equipment

 

Property, plant and equipment as of September 30, 2021 and June 30, 2021 included the following:

 

    09/30/2021     06/30/2021  
Gross carrying amount     65,468,079       63,974,402  
Accumulated depreciation     (17,389,336 )     (16,019,806 )
Net carrying amount     48,078,743       47,954,596  

 

  F-17  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS 

(Amounts in US Dollars, except otherwise indicated)

 

Net carrying amount for each class of assets is as follows:

 

Class   Net carrying
amount
09/30/2021
    Net carrying
amount
06/30/2021
 
Office equipment     233,701       288,920  
Vehicles     2,196,182       1,835,634  
Equipment and computer software     97,010       67,105  
Fixtures and fittings     3,327,794       2,967,431  
Machinery and equipment     5,166,486       5,125,728  
Land and buildings     35,183,123       35,674,513  
Buildings in progress     1,874,447       1,995,265  
Total     48,078,743       47,954,596  

 

1. Gross carrying amount as of September 30, 2021 is as follows:

 

    Gross carrying amount  
Class   As of the
beginning
of the
period
    Additions     Transfers     Disposals     Foreign
currency
translation
    Revaluation     As of the
end of the
period
 
Office equipment     762,825       5,290       (57,945 )     -       31,728       -       741,898  
Vehicles     3,512,217       380,671       57,945       -       173,881       -       4,124,714  
Equipment and computer software     592,126       35,904       -       (33,476 )     19,598       -       614,152  
Fixtures and fittings     5,637,943       -       336,147       -       463,824       -       6,437,914  
Machinery and equipment     9,987,811       104,452       -       (39,144 )     471,112       -       10,524,231  
Land and buildings     41,486,215       3,020       28,413       -       1,851,395       (2,218,320 )     41,150,723  
Buildings in progress     1,995,265       250,064       (364,560 )     (120,206 )     113,884       -       1,874,447  
Total     63,974,402       779,401       -       (192,826 )     3,125,422       (2,218,320 )     65,468,079  

 

2. Accumulated depreciation as of September 30, 2021 is as follows:

 

    Depreciation  
Class   Accumulated
as of the
beginning of
the period
    Disposals     Of the period     Foreign
currency
translation
    Revaluation     Accumulated
as of the end
of period
 
Office equipment     473,905       -     11,407       22,885       -       508,197  
Vehicles     1,676,583       -       220,281       31,668       -       1,928,532  
Equipment and computer software     525,021       (33,181 )      17,815       7,487       -       517,142  
Fixtures and fittings     2,670,512       -       289,507       150,101       -       3,110,120  
Machinery and equipment     4,862,083       (4,241 )     237,784       262,119       -       5,357,745  
Land and buildings     5,811,702       -       169,550       335,389       (349,041 )     5,967,600  
Total     16,019,806       (37,422 )     946,344       809,649       (349,041 )     17,389,336  

 

  F-18  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS 

(Amounts in US Dollars, except otherwise indicated)

 

3. Gross carrying amount as of September 30, 2020, is as follows:

 

    Gross carrying amount  
Class   As of the
beginning of
period
    Additions     Disposals     Foreign
currency
translation
    Revaluation     As of the end
of period
 
Office equipment     579,882       34,754       -       (2,884 )     -       611,752  
Vehicles     2,977,542       760,464       (56,338 )     (14,608 )     -       3,667,060  
Equipment and computer software     465,679       3,107       -       (1,208 )     -       467,578  
Fixtures and fittings     5,480,431       -       -       (26,135 )     -       5,454,296  
Machinery and equipment     9,054,701       48,202       -       (75,265 )     -       9,027,638  
Land and buildings     34,698,618       -       -       (120,985 )     149,399       34,727,032  
Buildings in progress     1,270,539       221,026       -       (5,864 )     -       1,485,701  
Total     54,527,392       1,067,553       (56,338 )     (246,949 )     149,399       55,441,057  

 

4. Accumulated depreciation as of September 30, 2020, is as follows:

 

    Depreciation  
Class   Accumulated
as of the
beginning of
period
    Disposals     Of the
period
    Foreign
currency
translation
    Revaluation     Accumulated
as of the end
of period
 
Office equipment     391,602       -       9,709       (1,177 )     -       400,134  
Vehicles     1,828,087       (54,279 )     139,019       (8,865 )     -       1,903,962  
Equipment and computer software     433,231       -       5,782       (1,741 )     -       437,272  
Fixtures and fittings     1,801,356       -       84,156       (8,943 )     -       1,876,569  
Machinery and equipment     3,605,468       -       139,300       (16,497 )     -       3,728,271  
Land and buildings     4,952,542       -       156,689       (21,767 )     5,132       5,092,596  
Total     13,012,286       (54,279 )     534,655       (58,990 )     5,132       13,438,804  

 

The depreciation charge is included in Notes 7.3 and 7.4.

 

Revaluation of property, plant and equipment

 

At a minimum, the Group updates its assessment of the fair value of its land and buildings at the end of each reporting year (after the revaluation policy was adopted), considering the most recent independent valuations and market data. As of September 30, 2021, the Group reviewed these valuations in order to determine the variations between the fair values and their book value, taking into consideration the valuations made in June 2021. Management determined the property, plant and equipment’s value within a range of reasonable fair value estimates. All resulting fair value estimates for land and buildings are classified as Level 3 and are consistent with the methodology disclosed in the annual financial statements.

 

6.8. Intangible assets

 

Intangible assets as of September 30, 2021 and June 30, 2021 included the following:

 

    09/30/2021     06/30/2021  
Gross carrying amount     82,263,734       78,019,203  
Accumulated amortization     (11,976,291 )     (10,676,841 )
Net carrying amount     70,287,443       67,342,362  

 

  F-19  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS 

(Amounts in US Dollars, except otherwise indicated)

 

1. Net carrying amount of each class of intangible assets is as follows:

 

Class   Net carrying
amount
09/30/2021
    Net carrying
amount
06/30/2021
 
Seed and integrated products                
HB4 soy and breeding program     28,964,455       27,611,142  
Integrated seed products     2,689,348       2,558,220  
Crop nutrition                
Microbiological products     4,243,569       3,996,657  
Other intangible assets                
Trademarks and patents     7,122,562       6,923,256  
Software     2,108,152       1,849,041  
Customer loyalty     20,159,357       19,404,046  
RG/RS/OX Wheat     5,000,000       5,000,000  
Total     70,287,443       67,342,362  

 

2. Gross carrying amount as of September 30, 2021 is as follows:

 

    Gross carrying amount  
Class   As of the
beginning of the period
    Additions     Foreign
currency
translation
    As of the end
of the period
 
Seed and integrated products                                
HB4 soy and breeding program     27,611,142       1,353,313       -       28,964,455  
Integrated seed products     2,558,220       -       131,128       2,689,348  
Crop nutrition                                
Microbiological products     6,037,680       233,729       273,721       6,545,130  
Other intangible assets                                
Trademarks and patents     9,824,171       629       544,834       10,369,634  
Software     3,784,593       191,504       282,051       4,258,148  
Customer loyalty     23,203,397       -       1,233,622       24,437,019  
RG/RS/OX Wheat     5,000,000       -       -       5,000,000  
Total     78,019,203       1,779,175       2,465,356       82,263,734  

 

3. Accumulated amortization as of September 30, 2021 is as follows:

 

    Amortization  
Class   Accumulated
as of
beginning of
the period
    Of the period     Foreign
currency
translation
    Accumulated
as of the end of
the period
 
Crop nutrition                                
Microbiological products     2,041,023       139,408       121,130       2,301,561  
Other intangible assets                                
Trademarks and patents     2,900,915       174,626       171,531       3,247,072  
Software     1,935,552       103,543       110,901       2,149,996  
Customer loyalty     3,799,351       255,310       223,001       4,277,662  
Total     10,676,841       672,887       626,563       11,976,291  

 

  F-20  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS 

(Amounts in US Dollars, except otherwise indicated)

 

4. Gross carrying amount as of September 30, 2020 is as follows:

 

    Gross carrying amount  
Class   As of the
beginning of
period
    Additions     Foreign
currency
translation
    As of the
end of
period
 
Seed and integrated products                                
HB4 soy and breeding program     7,345,923       439,934       (820 )     7,785,037  
Integrated seed products     2,296,955       -       (10,087 )     2,286,868  
Crop nutrition                                
Microbiological products     3,867,593       246,385       (16,272 )     4,097,706  
Other intangible assets                                
Trademarks and patents     8,432,746       -       (37,019 )     8,395,727  
Software     2,088,929       36,067       (19,296 )     2,105,700  
Customer loyalty     18,800,691       -       (82,532 )     18,718,159  
Total     42,832,837       722,386       (166,026 )     43,389,197  

 

5. Accumulated amortization as of September 30, 2020 is as follows:

 

    Amortization  
Class   Accumulated
as of
beginning of
period
    Of the period     Foreign
currency
translation
    Accumulated
as of the end
of period
 
Crop nutrition                                
Microbiological products     1,363,962       113,827       (5,181 )     1,472,608  
Other intangible assets                                
Trademarks and patents     2,057,964       138,441       (9,034 )     2,187,371  
Software     1,401,964       97,227       (15,290 )     1,483,901  
Customer loyalty     2,675,483       179,982       (11,745 )     2,843,720  
Total     7,499,373       529,477       (41,250 )     7,987,600  

 

The amortization charge is included in Notes 7.3 and 7.4.

 

6.9. Goodwill

 

The variations in goodwill that occurred during the period correspond to the result of inflation adjustment and conversion to presentation currency. There were no indicators of goodwill impairment.

 

Carrying amount of goodwill as of September 30, 2021 and June 30, 2021 is as follows:

 

    09/30/2021     06/30/2021  
Rizobacter Argentina S.A.     23,638,531       22,277,336  
Bioceres Crops S.A.     6,360,218       6,003,780  
Insumos Agroquímicos S.A.     470,090       470,090  
      30,468,839       28,751,206  

 

  F-21  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

6.10.    Trade and other payables

 

    09/30/2021     06/30/2021  
Current            
Trade creditors     88,718,299       51,389,515  
Shareholders and other related parties (Note 15)     36,920       52,864  
Trade creditors - Parent company (Note 15)     250,629       193,718  
Trade creditors - Joint ventures and associates (Note 15)     22,343,319       17,669,027  
Taxes     2,237,168       2,556,945  
Miscellaneous     376,983       229,339  
      113,963,318       72,091,408  

 

6.11.    Borrowings

 

    09/30/2021     06/30/2021  
Current                
Bank overdrafts     -       32,838  
Bank borrowings     29,156,974       33,684,287  
Corporate bonds     20,387,497       24,742,752  
Trust debt securities     2,102,497       3,470,448  
Net loans payables- Parents companies and related parties to Parents (Note 15)     3,578,921       3,578,921  
Subordinated loan     11,429,689       11,276,611  
      66,655,578       76,785,857  
Non-current                
Bank borrowings     2,656,673       4,161,827  
Corporate bonds     53,987,495       37,826,641  
Net loans payables- Parents companies and related parties to Parents (Note 15)     6,000,000       6,000,000  
      62,644,168       47,988,468  

 

On August 31, 2021, Rizobacter completed a $16.1 million public offering of Series VI corporate bonds in the Argentine market. The bonds were issued in two tranches: (i) Class A: $12.7 million with maturity in March 2023 and an annual nominal interest rate of 3.75%; and (ii) Class B: $3.4 million with maturity in September 2024 and an annual nominal interest rate of 5.25%.

 

The carrying value of some borrowings as of September 30, 2021 measured at amortized cost differs from the fair value of these borrowings. The following measures of fair values are based on discounted cash flows (Level 3), due to the use of unobservable inputs, including own credit risk.

 

    09/30/2021     06/30/2021  
    Amortized cost     Fair value     Amortized cost     Fair value  
Current                                
Bank borrowings     29,156,974       28,809,692       33,684,287       32,770,615  
Corporate Bonds     20,387,497       20,072,253       24,742,752       24,085,087  
                                 
Non-current                                
Bank borrowings     2,656,673       2,312,824       4,161,827       3,864,666  
Corporate Bonds     53,987,495       47,941,646       37,826,641       32,656,097  

 

The Group has met the capital and interest installments whose maturity was effective in the three-month period ended September 30, 2021.

 

  F-22  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

6.12.    Employee benefits and social security

 

    09/30/2021     06/30/2021  
Current            
Salaries, accrued incentives, vacations and social security     5,081,964       4,243,585  
Key management personnel (Note 15)     132,037       436,493  
      5,214,001       4,680,078  

 

6.13.    Consideration for acquisitions

 

The consideration of payment for the acquisitions was measured at fair value, which was calculated as the sum of the acquisition-date fair values of the assets transferred, and the liabilities incurred. The fair values measured were based on discounting future cash flow using market discount rates. The difference between fair value and nominal value of consideration is recognized as other finance over the period the consideration will be paid.

 

7.          INFORMATION ABOUT COMPONENTS OF UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

 

7.1.      Revenues from contracts with customers

 

    09/30/2021     09/30/2020  
Sale of goods and services     65,672,217       41,193,013  
Royalties     681,657       912,277  
      66,353,874       42,105,290  

 

Transactions of sales of goods and services with joint ventures, shareholders and other related parties are reported in Note 15.

 

7.2.      Cost of sales

 

Item   09/30/2021     09/30/2020  
Inventories as of the beginning of the period     39,052,925       29,338,548  
Purchases of the period     49,130,173       23,197,990  
Production costs     3,662,191       2,922,581  
Foreign currency translation     2,534,476       (404,642 )
Subtotal     94,379,765       55,054,477  
Inventories as of the end of the period (*)     (56,497,312 )     (31,941,835 )
Cost of sales     37,882,453       23,112,642  

 

(*) Net of agricultural products from the HB4 program.

 

  F-23  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

7.3.      R&D classified by nature

  

Item   Research and
development
expenses
09/30/2021
    Research and
development
expenses
09/30/2020
 
Amortization of intangible assets     302,214       252,267  
Import and export expenses     1,686       2,533  
Depreciation of property, plant and equipment     179,677       32,423  
Freight and haulage     12       -  
Employee benefits and social securities     259,522       210,327  
Maintenance     7,375       4,791  
Energy and fuel     18,521       14,019  
Supplies and materials     491,964       244,173  
Mobility and travel     4,766       4,274  
Professional fees and outsourced services     62,856       7,447  
Professional fees related parties     86,256       234,837  
Office supplies     2,334       493  
Information technology expenses     31       9,915  
Insurance     2,960       5,653  
Depreciation of leased assets     1,206       654  
Miscellaneous     10,162       406  
Total     1,431,542       1,024,212  

 

    09/30/2021     09/30/2020  
R&D Capitalized (Note 6.8)     1,587,042       439,934  
R&D profit and loss     1,431,542       1,024,212  
Total     3,018,584       1,464,146  

 

  F-24  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

7.4.      Expenses classified by nature and function

 

Item   Production costs     Selling, general
and administrative
expenses
    Total 09/30/2021  
Amortization of intangible assets     -       370,673       370,673  
Analysis and storage     2,355       24,703       27,058  
Commissions and royalties     335,585       473,456       809,041  
Import and export expenses     7,304       159,345       166,649  
Depreciation of property, plant and equipment     314,569       452,098       766,667  
Depreciation of leased assets     118,086       120,862       238,948  
Impairment of receivables     -       197,642       197,642  
Freight and haulage     98,488       2,221,651       2,320,139  
Employee benefits and social securities     1,508,725       4,997,301       6,506,026  
Maintenance     178,832       211,075       389,907  
Energy and fuel     105,690       15,593       121,283  
Supplies and materials     209,874       129,419       339,293  
Mobility and travel     4,454       265,364       269,818  
Publicity and advertising     -       973,659       973,659  
Contingencies     -       2,742       2,742  
Share-based incentives     -       517,434       517,434  
Professional fees and outsourced services     307,060       1,971,702       2,278,762  
Professional fees related parties     -       14,474       14,474  
Office supplies     6,376       119,830       126,206  
Insurance     13,054       240,421       253,475  
Information technology expenses     -       330,337       330,337  
Obsolescence     440,324       -       440,324  
Taxes     11,256       2,331,803       2,343,059  
Miscellaneous     159       41,616       41,775  
Total     3,662,191       16,183,200       19,845,391  

 

  F-25  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

Item   Production costs     Selling, general
and administrative
expenses
    Total 09/30/2020  
Amortization of intangible assets     -       277,210       277,210  
Analysis and storage     11,562       9,674       21,236  
Commissions and royalties     468,400       155,743       624,143  
Import and export expenses     41,244       233,814       275,058  
Depreciation of property, plant and equipment     270,785       231,447       502,232  
Depreciation of leased assets     64,014       28,499       92,513  
Impairment of receivables     -       96,931       96,931  
Freight and haulage     162,690       997,397       1,160,087  
Employee benefits and social securities     1,198,492       3,366,048       4,564,540  
Maintenance     165,489       175,437       340,926  
Energy and fuel     80,009       22,326       102,335  
Supplies and materials     60,192       77,134       137,326  
Mobility and travel     968       162,001       162,969  
Publicity and advertising     -       462,658       462,658  
Contingencies     4,403       33,386       37,789  
Share-based incentives     -       316,703       316,703  
Professional fees and outsourced services     173,131       1,748,720       1,921,851  
Professional fees related parties     -       2,294       2,294  
Office supplies     378       122,357       122,735  
Insurance     18,648       225,789       244,437  
Information technology expenses     328       247,928       248,256  
Obsolescence     192,170       -       192,170  
Taxes     9,298       1,081,550       1,090,848  
Miscellaneous     380       17,197       17,577  
Total     2,922,581       10,092,243       13,014,824  

 

7.5.      Finance results

 

    09/30/2021     09/30/2020  
Financial costs                
Interest expenses with the Parents (Note 15)     (240,639 )     (313,677 )
Interest expenses     (2,312,445 )     (4,490,817 )
Financial commissions     (789,725 )     (471,556 )
      (3,342,809 )     (5,276,050 )
Other financial results                
Exchange differences generated by assets     4,721,459       8,480,343  
Exchange differences generated by liabilities     (7,441,398 )     (12,055,520 )
Changes in fair value of financial assets or liabilities and other financial results     (766,225 )     (5,459,905 )
Net gain of inflation effect on monetary items     1,649,305       1,575,670  
      (1,836,859 )     (7,459,412 )
                 
Total net financial results     (5,179,668 )     (12,735,462 )

 

  F-26  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

8.            TAXATION

 

Taxes on income in the interim periods are accrued using the tax rate that would be applicable to expected total annual earnings.

 

    09/30/2021     09/30/2020  
Current tax expense     (4,650,198 )     (2,360,843 )
Deferred tax     2,054,885       354,977  
Total     (2,595,313 )     (2,005,866 )

 

The gross movement on the deferred income tax account is as follows:

 

    09/30/2021     09/30/2020  
Beginning of the period deferred tax     (22,421,125 )     (14,164,930 )
Charge of the period     2,054,885       354,977  
Charge to OCI     654,248       (36,067 )
Conversion difference     (1,451,115 )     30,922  
Total net deferred tax     (21,163,107 )     (13,815,098 )

 

The tax on the Group’s profit before tax differs from the theoretical amount that would arise using the weighted average tax rate applicable to profits of the consolidated entities as follows:

 

    09/30/2021     09/30/2020  
Earnings (Loss) before income tax-rate     4,860,529       (4,364,396 )
Income tax expense by applying tax rate in force in the respective countries     (2,774,368 )     (1,306,510 )
Share of profit or loss of subsidiaries, joint ventures and associates     (78,009 )     82,195  
Stock options charge     (93,824 )     (15,212 )
Rate change adjustment     -       38,109  
Non-deductible expenses     (475,473 )     (70,883 )
Untaxed gains     135,263       -  
Representation expenses     (2,084 )     (8,189 )
Foreign investment coverage     56,980       99,610  
Tax inflation adjustment     300,200       (742,393 )
Result of inflation effect on monetary items and other finance results     283,261       (82,593 )
Others     52,741       -  
Income tax expenses     (2,595,313 )     (2,005,866 )

 

  F-27  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

9.            EARNINGS PER SHARE (EPS)

 

The numerators and denominators used in the calculation of basic EPS and diluted EPS are presented below:

 

    09/30/2021     09/30/2020  
Numerator            
Profit (loss) for the period (basic EPS)     874,137       (6,971,558 )
Profit (loss) for the period (diluted EPS)     874,137       (6,971,558 )
Denominator                
Weighted average number of shares (basic EPS)     41,104,088       36,367,953  
Weighted average number of shares (diluted EPS)     42,376,794       36,367,953  
                 
Basic profit (loss) attributable to ordinary equity holders of the parent     0.0213       (0.1917 )
                 
Diluted profit (loss) gain attributable to ordinary equity holders of the parent     0.0206       (0.1917 )

 

For the period ended September 30, 2020 diluted EPS was the same as basic EPS as the effect of potential ordinary shares would be antidilutive.

 

Diluted earnings per share is calculated by adjusting the weighted average number of shares outstanding to assume conversion of all dilutive potential shares. The Group has two categories of dilutive potential shares, share-based incentives, and Convertible notes.

 

The stock options were included in the diluted EPS calculation for the year ended Septiember 30, 2021 only for the tranches in which the average market price of ordinary shares during the periods was higher than the assumed proceeds per option. See note 17.

 

Convertible notes outstanding were not included in the diluted EPS calculations for the year ended September 30, 2021 because its interest (net of tax and other changes in income or expense) per ordinary share obtainable on conversion exceeds basic earnings per share.

 

10.            INFORMATION ABOUT UNAUDITED INTERIM CONDENSED CONSOLIDATED COMPONENTS OF EQUITY

 

Share capital

 

As of September 30, 2021, we have (i) 100,000,000 ordinary shares ($0.0001 par value) authorized, (ii) 41,104,087 ordinary shares issued and outstanding, (iii) 1,000,000 preference shares ($0.0001 par value) authorized, (iv) no preference shares issued and outstanding, (v) $49.1 million of Convertible notes, and (vi) 2,032,092 ordinary shares reserved for our equity compensation plans.

 

Holders of the ordinary shares are entitled to one vote for each ordinary share.

 

Non-controlling interests

 

On August 2, 2021, we acquired 2,467,990 shares of Insumos Agróquimicos S.A. (“Insuagro”). Consideration of payment was $0.7 million in cash as a Fixed Price. Furthermore, the Fixed Price may be increased up to 3.5x Adjusted EBITDA per share to be measured in each annual reporting period. The Group has recognized in equity the difference between the amount by which the non-controlling interests were incorporated and the fair value of the consideration paid.

 

As of today, we own 13,489,990 shares of Insuagro, which represent 61.32% of the share capital and 61.22% of the votes.

 

There were no dividends paid to non-controlling interests in the periods ended September 30, 2021 and 2020.

 

  F-28  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

11. CASH FLOW INFORMATION

 

Significant non-cash transactions related to investment and financing activities are as follows:

 

    09/30/2021     09/30/2020  
Investment activities                
Settlement of receivables through PPE contribution     -       1,858,732  
Investment in-kind in other related parties (Note 15)     455,444       261,619  
      455,444       2,120,351  

 

    09/30/2021     09/30/2020  
Financing activities                         
                 
Acquisition of non-controlling interest in subsidiaries     255,893       -  
      255,893       -  

 

12. JOINT VENTURES AND ASSOCIATES

 

    09/30/2021     06/30/2021  
Liabilities                
Trigall Genetics S.A.     1,276,639       1,278,250  
      1,276,639       1,278,250  

 

    09/30/2021     06/30/2021  
Assets                
Synertech Industrias S.A.     28,780,636       27,572,597  
Indrasa Biotecnología S.A.     69,709       54,957  
Alfalfa Technologies S.R.L.     94,922       97,920  
Moolec Science Limited     2,931,699       2,931,699  
      31,876,966       30,657,173  

 

Share of profit or loss of joint ventures and associates:

 

    09/30/2021     09/30/2020  
Trigall Genetics S.A.     1,611       (114,233 )
Synertech Industrias S.A.     (240,282 )     328,106  
Indrasa Biotecnología S.A.     16,435       25,839  
      (222,236 )     239,712  

 

Changes in joint ventures and associates

 

    09/30/2021     09/30/2020  
As of the beginning of the period     29,378,923       23,103,963  
Revaluation of property, plant and equipment     (173,852 )     14,135  
Foreign currency translation     1,617,492       (76,438 )
Share of profit or loss     (222,236 )     239,712  
As of the end of the period     30,600,327       23,281,372  

 

  F-29  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

13. SEGMENT INFORMATION

 

The following tables present information with respect to the Group´s reporting segments:

 

Period ended September 30, 2021   Seed and
integrated
products
    Crop
protection
    Crop
nutrition
    Consolidated  
Revenues from contracts with customers                                
Sale of goods and services     8,250,549       34,958,979       22,462,689       65,672,217  
Royalties     681,657                       681,657  
Others                                
Government grants     468       -       -       468  
Initial recognition and changes in the fair value of biological assets     45,951       191,317       314,635       551,903  
Total     8,978,625       35,150,296       22,777,324       66,906,245  
                                 
Cost of sales     (3,494,180 )     (21,524,899 )     (12,863,374 )     (37,882,453 )
Gross margin per segment     5,484,445       13,625,397       9,913,950       29,023,792  
%     61 %     39 %     44 %     43 %

 

Period ended September 30, 2020   Seed and
integrated
products
    Crop
protection
    Crop
nutrition
    Consolidated  
Revenues from contracts with customers                                
Sale of goods and services     7,742,299       21,567,520       11,883,194       41,193,013  
Royalties     912,277                       912,277  
Others                                
Government grants     604       -       -       604  
Initial recognition and changes in the fair value of biological assets     20,421       72,295       156,651       249,367  
Total     8,675,601       21,639,815       12,039,845       42,355,261  
                                 
Cost of sales     (3,320,422 )     (13,521,273 )     (6,270,947 )     (23,112,642 )
Gross margin per segment     5,355,179       8,118,542       5,768,898       19,242,619  
%     62 %     38 %     48 %     45 %

 

  F-30  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

14.            FINANCIAL INSTRUMENTS – RISK MANAGEMENT

 

The following tables show additional information required under IFRS 7 for financial assets and liabilities recorded as of September 30, 2021 and June 30, 2021.

 

    Amortized cost     Mandatorily measured at fair
value through profit or loss
 
Financial asset   09/30/2021     06/30/2021     09/30/2021     06/30/2021  
Cash and cash equivalents     30,082,841       28,327,569       6,548,708       7,718,544  
Other financial assets     1,188,325       1,523,438       5,031,211       10,735,422  
Trade receivables     94,938,434       88,919,911       -       -  
Other receivables (*)     5,228,282       5,005,283       -       -  
Total     131,437,882       123,776,201       11,579,919       18,453,966  

 

(*) Advances expenses and tax balances are not included.

 

    Amortized cost     Mandatorily measured at fair
value through profit or loss
 
Financial liability   09/30/2021     06/30/2021     09/30/2021     06/30/2021  
Trade and other payables     113,963,318       72,091,408                 -                   -  
Borrowings     129,299,746       124,774,325       -       -  
Convertible notes     50,190,617       48,664,012       -       -  
Lease liability     1,209,067       1,140,717       -       -  
Employee benefits and social security     5,214,001       4,680,078       -       -  
Consideration for acquisition of assets     12,075,576       11,790,533       -       -  
Total     311,952,325       263,141,073       -       -  

 

Financial instruments measured at fair value

 

Measurement at fair value at 09/30/2021   Level 1     Level 2     Level 3  
Financial assets at fair value                               
Mutual funds     6,548,708       -       -  
US Treasury bills     2,513,798       -       -  
Other investments     1,883,593       633,820       -  

 

Measurement at fair value at 06/30/2021   Level 1     Level 2     Level 3  
Financial assets at fair value                                 
Mutual funds     7,718,544       -       -  
US Treasury bills     7,885,937       -       -  
Other investments     2,110,414       739,071       -  

 

  F-31  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

Estimation of fair value

 

The fair value of marketable securities, mutual funds and US Treasury Bills is calculated using the market approach, which use quoted prices in active markets for identical assets. The quoted marked price used for financial assets held by the Group is the current bid price. These instruments are included in level 1.

 

The Group’s financial liabilities, which were not traded in an active market, were determined using valuation techniques that maximize the use of available market information, and thus rely as little as possible on specific estimates. If all significant inputs required to fair value an instrument are observable, the instruments are included in level 2.

 

If one or more of the significant inputs is not based on observable market data, the instruments are included in Level 3.

 

The Group’s policy is to recognize transfers between different categories of the fair value hierarchy at the time they occur or when there are changes in the circumstances that cause the transfer.

 

There were no transfers between levels of the fair value hierarchy. There were no changes in economic or business circumstances affecting fair value.

 

Financial instruments not measured at fair value

 

The financial instruments not measured at fair value include cash and cash equivalents, trade accounts receivable, other accounts receivable, trade payables and other debts, borrowings, financed payments and convertible notes.

 

The carrying value of financial instruments not measured at fair value does not differ significantly from their fair value, except for borrowings (Note 6.11).

 

Management estimates that the carrying value of the financial instruments measured at amortized cost approximates their fair value.

 

15. SHAREHOLDERS AND OTHER RELATED PARTIES BALANCES AND TRANSACTIONS

 

During the periods ended September 30, 2021 and 2020, the transactions between the Group and related parties, and the related balances owed by and to them, are as follows:

 

        Amount of the transactions of the period ended  
Party   Transaction type   09/30/2021     09/30/2020  
Joint ventures and associates   Sales and services     4,331,275       1,340,709  
Joint ventures and associates   Purchases of goods and services     (12,087,333 )     (4,496,924 )
Joint ventures and associates   Net loans granted     -       375,575  
Key management personnel   Salaries, social security benefits and other benefits     (969,716 )     (880,195 )
Key management personnel   Net loans cancelled     -       (598,508 )
Key management personnel   Interest gain     -       8,812  
Shareholders and other related parties   Sales of goods and services     1,805       177,017  
Shareholders and other related parties   Purchases of goods and services     (1,422,314 )     (492,235 )
Shareholders and other related parties   In-kind contributions     455,444       261,619  
Parents companies and related parties to Parents (Note 7.5)   Interest expenses     (240,639 )     (313,677 )
Total         (9,931,478 )     (4,617,807 )

 

  F-32  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

        Amounts receivable from related parties  
Party   Transaction type   09/30/2021     06/30/2021  
Parents companies and related parties to Parents   Other receivables     1,052,879       770,549  
Shareholders and other related parties   Trade debtors     (78,474 )     -  
Shareholders and other related parties   Allowance for impairment     43,345       -  
Other receivables - Other related parties   Other receivables     130,064       134,172  
Joint ventures and associates   Trade debtors     57,706       221,048  
Joint ventures and associates   Other receivables     2,375,118       2,219,863  
Total         3,580,638       3,345,632  

 

        Amounts payable to related parties  
Party   Transaction type   09/30/2021     06/30/2021  
Parent company   Trade creditors     (250,629 )     (193,718 )
Parents companies and related parties to Parents   Net loans payables     (9,578,921 )     (9,578,921 )
Key management personnel   Salaries, social security benefits and other benefits     (132,037 )     (436,493 )
Shareholders and other related parties   Trade and other payables     (36,920 )     (52,864 )
Joint ventures and associates   Trade creditors     (22,343,319 )     (17,669,027 )
Total         (32,341,826 )     (27,931,023 )

 

16. KEY MANAGEMENT PERSONNEL COMPENSATION

 

The compensation of directors and other members of key management, including social security contributions and other benefits, was as follows for the period ended September 30, 2021 and 2020.

 

    09/30/2021     09/30/2020  
Salaries, social security and other benefits     452,282       563,492  
Share-based incentives     517,434       316,703  
Total     969,716       880,195  

 

17. SHARE-BASED PAYMENTS

 

a) Incentive payments based on options

 

-    Share option plan for directors and senior management: plan granted up to 1,200,000 stock options with an exercise price of $4.55 and expire on October 31, 2029.

 

-    Share Option Plan for junior management: plan granted up to 100,000 underlying ordinary shares for certain key employees. The options have an exercise price of $5.55 and expire on October 23, 2030.

 

Options can be exercised on a cashless basis at their volume weighted average price (“VWAP”) of the ordinary shares during a twenty-day period to the date of exercise.

 

  F-33  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

The fair value of the stock options at the grant date was estimated using the "Black-Scholes" model, considering the terms and conditions under which the options on shares were granted and adjusted to consider the possible dilutive effect of the future exercise of options.

 

Factor   Directors and
Sr. Management
    Junior
Management
 
Weighted average fair value of shares   $ 5.42     $ 13.98  
Exercise price   $ 4.55     $ 5.55  
Weighted average expected volatility (*)     29.69 %     42.18 %
Dividend rate     0 %     0 %
Weighted average risk-free interest rate     1.66 %     1.17 %
Weighted average expected life     9.89 years     9.22 years
Weighted average fair value of stock options at measurement date   $ 2.47     $ 10.1  

 

There are no market-related performance conditions or non-vesting conditions that should be considered for determining the fair value of options.

 

The Group estimates that 100% of the stock options will be exercised, taking into account historical patterns of executives maintaining their jobs and the probability of exercising the options. This estimate is reviewed at the end of each annual or interim period.

 

The following table shows the weighted average amount and exercise price and the movements of the stock options of executives and directors of the Group during the three-month periods ended September 30, 2021 and 2020.

 

    09/30/2021     09/30/2020  
    Number of
options
    Exercise
price
    Number of
options
    Exercise
price
 
At the beginning     1,166,667     $ 4.55       1,200,000     $ 4.55  
Granted during the period     93,600     $ 5.55       -       -  
Annulled during the period     -       -       -       -  
Exercised during the period     -       -       -       -  
Expired during the period     -       -       -       -  
Effective at period (*)     1,260,267     $ 4.62       1,200,000     $ 4.55  

 

(*) Exercise price of options effective at the end of the period was calculated using weighted average.

 

The charge of the plans based on options recognized during the period was $0.4 million.

 

b) Annual compensation - Bonus

 

Bonus in Cash is an annual cash incentive awarded up to an amount that is five times the individual’s monthly salary, which can be increased by $30,000 in value if the recipient decides to receive the base bonus in ordinary shares, to each of the Chief Operating Officer, Sales Director and Marketing Director and Managing Director of Rizobacter. The bonus will be granted upon the meeting by the Company of certain financial and operational objectives. Each year the Board of Directors defines the objectives upon approval of the annual budget.

 

As well as fiscal year ended June 30, 2020, for the Bonus in Cash 2021, all the beneficiaries decided to receive the bonus in ordinary shares. The charge for the three-month period ended September 30, 2021 in consideration of the annual compensation bonus for objectives achieved in the year ended June 30, 2021 amounted to $0.05 million.

 

  F-34  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

Bonus in Kind is an annual in-kind incentive awarded in ordinary shares up to an equivalent of $315,000, $165,000 and $100,000 to the Chief Executive Officer, Chief Financial Officer and Chief Technology Officer, respectively, to tie a portion of their compensation to financial and operational objectives. Each year the Board of Directors will define the objectives upon approval of the annual budget.

 

The charge for the three-month period ended September 30, 2021 in consideration of the annual compensation bonus for objectives achieved in the year ended June 30, 2021 amounted to $0.07 million.

 

The number of shares that can be awarded under each bonus will be determined by using a 20-day volume weighted average price (“VWAP”) of the Company’s ordinary shares, starting with the day on which the relevant financial and operational objectives are met by the Company and the bonus is granted.

 

50% of bonus vests immediately if the financial and operational objectives are achieved as of such date, and the remaining 50% vests in the subsequent 12-months, upon meeting of the financial and operational objectives.

 

e) Employee Stock Purchase Plan (ESPP)

 

This is an incentive plan for eligible employees with no stock compensation to purchase ordinary shares of the Company up to a maximum of 15% percent of such employee’s monthly compensation. The number of ordinary shares subject to the ESPP shall be 200,000 ordinary shares. The purchase price will be equal to 85% of the lower of the closing price of the Company’s ordinary shares on the first business day and the last business day of the relevant offering period. As of the date of These condensed consolidated statements of financial position the ESSP is not yet implemented.

 

18. LEASE

 

Right-of-use leased asset   09/30/2021     06/30/2021  
Cost                
Book value at the beginning of the period     3,688,150       2,369,326  
Additions of the period     307,510       913,321  
Disposals     (44,092 )     -  
Exchange differences     (82,907 )     405,503  
Book value at the end of the year     3,868,661       3,688,150  

 

Depreciation   09/30/2021     06/30/2021  
Book value at the beginning of the period     2,360,490       1,254,729  
Exchange differences     (139,137 )     278,441  
Depreciation of the period     240,154       827,320  
Accumulated depreciation at the end of the period     2,461,507       2,360,490  
Total     1,407,154       1,327,660  

 

Lease liability   09/30/2021     06/30/2021  
Book value at the beginning of the period     1,140,717       1,109,812  
Additions of the year     106,185       259,427  
Interest expenses, exchange differences and inflation effects     205,948       500,442  
Payments of the period     (243,783 )     (728,964 )
Total     1,209,067       1,140,717  

 

Lease Liabilities   09/30/2021     06/30/2021  
Non-current     490,101       390,409  
Current     718,966       750,308  
Total     1,209,067       1,140,717  

 

  F-35  

 

 

BIOCERES CROP SOLUTIONS CORP.

 

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US Dollars, except otherwise indicated)

 

The recognized right-of-use assets relate to the following types of assets:

 

    09/30/2021     06/30/2021  
Machinery and equipment     700,807       661,544  
Vehicles     1,042,169       1,061,184  
Equipment and computer software     772,777       582,101  
Land and buildings     1,352,908       1,383,321  
      3,868,661       3,688,150  

 

The incremental borrowing rate used was 6.23%.

 

19. CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS

 

There were no significant changes to the contingencies, commitments and restrictions on the distribution of profits from the disclosure made in the Consolidated financial statement as of June 30, 2021.

 

20. EVENTS OCCURRING AFTER THE REPORTING PERIOD

 

Subsequent to September 30, 2021, there have been no situations or circumstances that may require significant adjustments or further disclosure in these unaudited interim condensed consolidated financial statements that were not mentioned above.

 

  F-36